|
ORF cDNA clones
|
CRISPR / TALEN
|
Lentivirus
|
AAV
|
TALE-TF
|
ORF knockin clones
|
|
Antibody
|
Proteins
|
miRNA target clones
|
qPCR primers
|
shRNA clones
|
miRNA products
|
Promoter clones
|
Validated All-in-One™ qPCR Primer for IGFBP2(NM_000597.2) Search again
Product ID:
HQP009541
(click here to view gene annotation page)
Powered by BiozSpecies:
Human
Symbol:
Alias:
IBP2, IGF-BP53
Gene Description:
insulin like growth factor binding protein 2
Target Gene Accession:
NM_000597.2(click here to view gene page)
Estimated Delivery:
Approximately 1-3 weeks, but may vary. Please email sales@genecopoeia.com or call 301-762-0888 to confirm ETA.
Important Note:
By default, qPCR primer pairs are designed to measure the expression level of the splice variant (accession number) you selected for this gene WITHOUT consideration of other possible variants of this gene. If this gene has multiple variants, and you would like to measure the expression levels of one particular variant, multiple variants, or all variants, please contact us for a custom service project at inquiry@genecopoeia.com.
Validated result:
|
|
| A | B |
|
Each All-in-One™ qPCR Primer is experimentally validated to yield a single dissociation curve peak and to generate a single amplification of the correct size for the targeted gene. A cDNA Pool, containing reverse transcript products of 8 different human tissue total RNA(Liver, Testis,Muscle,Thyroid,Brain,Spleen,Stomach,Small Intestine)),was used as the qPCR validation template. qPCR was performed using 0.2 µM primer with 2XAll-in-One™ qPCR Mix (Catalog#: QP001,QP002,QP004,QP005). Reactions were incubated for 10min. at 95°C, followed by 40 cycles of 95°C for 10 sec.; 60°C, 20 sec. and 72°C, 15sec. using Bio-Rad iQ5™ Instrument. At the end of the last cycle, temperature was increased from 72 to 95°C to produce a melting curve. Panel A: Validated Result for Amplification Curve; Panel B: Validated Result for Melting Curve. |
|
Gene References into function
- determination of blood levels in adult patients with severe liver disease before and after orthotopic liver transplantation
- Elevated level of IGFBP-2 is associated with pleural effusions of solid tumors
- data demonstrate for the first time that serum levels of IGFs (including free fractions) and IGFBPs are not increased in euthyroid Graves' patients with active thyroid eye disease
- IGFBP-2 may play a role in the progression, but not in the initiation of the prostate cancer disease process, suggesting the existence of a molecular switch transitioning IGFBP-2 from a growth inhibitor to a pro-carcinogenic molecule
- Data suggest that insulin-like growth factor-II (IGF-II) is complexed in vivo with intact insulin-like growth factor binding proteins (IGFBP-2) and with processed IGFBP-2 fragments, which do not impair the activity of IGF-II on cell survival.
- Castration-induced increases in this protein promotes proliferation of androgen-independent human prostate LNCaP tumors.
- Data provide evidence that IGFBP2 contributes to glioma progression in part by enhancing MMP-2 gene transcription and in turn tumor cell invasion.
- IGF-II-stimulated IGFBP-2 production appears to inhibit the mitogenic effect of IGF-II, and may have an autocrine effect on the maturation, differentiation, and survival of fetal podocytes.
- IGF-1, IGFBP-2 levels were related to IL levels, disease activity and anatomical distribution, consistent with active inflammation modifying the IGF-IGFBP system, possibly relevant to disturbance of growth.
- effect of IGFBP-2 overexpression on the activity of various antioxidative enzymes in two malignant cell lines
- IGFBP2 expression increases from benign and dysplastic nevi to primary and metastatic melanomas and suggests that it may play a role in melanoma progression.
- Of all the IGFBPs, only IGFBP-2 is expressed in activated microglia/macrophages; therefore IGFBP-2 may have an important role in IGF-I actions in human brain.
- Data demonstrate that insulin-like growth factor binding protein-2 can act in an IGF-independent manner, at least in part by an interaction with alpha5beta1-integrin.
- These findings suggest that overexpression of IGFBP-2 induces an increase in MMP-2 production, resulting in the enhanced metastatic potential of bladder cancer.
- 1,25-Dihydroxyvitamin D3 decreased mRNA levels of the growth stimulatory IGFBP-2 and induced IGFBP-3 mRNA in prostate cancer cells
- The expression of certain IGFBP is significantly altered in renal cell carcinoma
- IGFBP2 enhances the invasion capacity of ovarian cancer cells
- leptin and the IGF system of IGF-I, IGFBP-2, and IGF-I receptor do not interact directly in a cell culture model of neuroepithelioma cells
- C-domain of IGFBP-2 plays a key role in binding regions of IGF-I and -II that are also involved in binding to the type-1 IGF receptor and thereby blocking ligand binding to this receptor
- The heparin binding domain of IGFBP-2 is involved in the control and regulation of neuroblastoma growth and invasion.
- These results suggest that the mechanism of action whereby IGFBP2 excess impairs long bone development is to inhibit IGF-mediated proliferation and matrix synthesis.
- Regions upstream and downstream of the CWCV motif in IGFBP2 participate in IGF-1 binding.
- Acute myelocytic leukemia patienets with elevated IGFBP2 concentrations had a poorer outcome after sten cell transplantation.
- there are several conserved residues in the IGFBP-5 N-terminal region that are critical for transactivation and IGFBP-2 and -3 also have strong transactivation activity in their N-domains
- one mechanism by which IGFBP2 activates IGFBP2-induced cell mobility is through its interaction with integrin alpha5 and this interaction is specifically mediated through the RGD domain on IGFBP2
- High expression of insulin-like growth factor binding protein-2 messenger RNA is associated with epithelial ovarian cancers
- IGFBP-2 as a marker for antiestrogen resistant breast cancer cell lines.
- Results suggest that IGFBP-2-induced gene expressions are of functional significance for proliferation, cell adhesion, cell migration and apoptosis, and showed that IGFBP-2 can promote apoptosis in tumor cells independent of IGF.
- the solution structure of the C-terminal domain of IGFBP-2 was determined and its backbone dynamics based on 15N relaxation parameters analyzed with NMR.
- These findings suggest that continuous K-Ras activation accelerates cell growth and evokes a feedback system through IGFBP-4/2 to prevent excessive growth.
- IGFBP-2 may be involved in carcinogenesis and progression of gastric carcinoma by promoting cell proliferation.
- p53 protein binds IGFBP-2 intronic sequences in an electrophoretic mobility shift assay, and activates transcription in a luciferase assay.
- circulating levels significantly higher in cancer patients than in controls
- This is the first evidence for PKA-dependent regulation of IGFBP-2 expression in adrenocortical cells.
- Overexpression of the IGFBP-2 is associated with astrocytomas
- IGFBP-2 is regulated predominantly through the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway
- The results provide further evidence that IGFBP-2 and IGF-II in breast milk are relevant factors for the early development of preterm infants.
- Higher serum IGFBP-2, which is predictive of lower BMD, is associated with increased markers of bone resorption, independent of age, body mass, and sex hormones.
- IGF-II and IGFBP-2 differentially regulate PTEN in human breast cancer cells
- PTEN and IGFBP-2 expression are inversely correlated in human brain and prostate cancers
- Study found decreased IGFBP-2 expression in bipolar disorder patients compared with controls; this was especially pronounced in subjects not treated with lithium.
- CD24 is modulated by IGFBP-2 and contributes to IGFBP-2-enhanced invasiveness of glioblastoma cells
- IGFBP-2 has roles in the CNS and in the demyelinating disease MS [review]
- IGFBP2 plays a key role in activation of the Akt pathway and collaborates with K-Ras in the development and progression of two major types of glioma.
- [(125)I]-labeled IGFBP-2 and -3, but not IGFBP-1, were proteolyzed by Ca(2+)-activated m-calpain in vitro.
- Variations confer impaired glucose- and tolbutamide-induced insulin release in middle-aged and young healthy subjects.
- As well as other types of carcinomas, overexpression of IGFBP-2 has been reported in glioblastoma multiforme (GBM), the most malignant brain tumor characterized by rapid growth, extensive invasiveness, and angiogenesis.
- analyzed the molecular interactions among the N-domain of IGFBP-2 (N-BP-2), C-BP-2, and IGFs using cross-linking and nuclear magnetic resonance (NMR) spectroscopy
- Single nucleotide polymorphisms in IGFBP2 is associated with breast cancer
- IGFBP-2 may have a role in relapse of childhood acute lymphoblastic leukemia
- Higher early levels of the human milk IGF system might contribute to maturation of the infant gut.
- IGFBP2 and IGFBP5 play a role in the development of metastasis and may serve as useful markers to predict lymph node metastasis in patients with small (T1) invasive breast carcinomas.
- Markedly elevated IGF-II and IGFBP-2 serum levels in patients with non-seminomatous germ cell cancer, showing a significant decrease after successful therapy and an increase in recurrent disease.
- novel role of naturally occurring IGFBP-2 fragments for the endocrine and paracrine/autocrine regulation of longitudinal growth of growth plate chondrocytes
- These findings suggest insulin-like growth factor-binding protein-2 plays a role in astrocytoma progression by promoting DNA-damage repair and therapeutic resistance.
- Over-expression of mRNA levels of IGFBP-2 and CDC20 is highly related to glioblastomas.
- This study provides evidence that IGFBP-2 expression is associated with breast cancer.
- Results suggest that the growth-promoting role of IGFBP-2 in prostate cancer is inhibited by its intracellular interaction with PAPA-1.